Adriana Rossi, MD, of the Icahn School of Medicine at Mount Sinai, and Jack Khouri, MD, of the Taussig Cancer Center, met with Blood Cancers Today to discuss two studies on selinexor in relapsed or refractory patients with multiple myeloma presented at the 21st International Myeloma Society Annual Meeting.
The first study was a real-world analysis describing the impact of prior selinexor exposure on chimeric antigen receptor T-cell (CAR-T) therapy outcomes in relapsed or refractory multiple myeloma.
Based on the data, Dr. Rossi and Dr. Khouri concluded that prior selinexor therapy did not compromise expected response or survival outcomes of CAR-T therapy in heavily pretreated patients.
The second poster presentation was an exploratory analysis of survival after CAR-T therapy in selinexor-exposed patients. Dr. Rossi noted that bispecifics currently used as bridging therapies prior to CAR-T can lead to T-cell depletion. Conversely, the exploratory data supported that selinexor could be a T-cell sparing bridging regimen.
“I think the hope is that selinexor used prior to apheresis as well as in bridging could have beneficial effects on the T-cell phenotype,” Dr. Rossi said.
Dr. Khouri discussed one of the more notable observations in the exploratory analysis. “What was really interesting about patients who received selinexor immediately before apheresis, they did have a survival advantage after CAR-T therapy,” he said.